Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Bacteria or actinomycetales
Reexamination Certificate
1999-06-30
2002-04-09
Prats, Francisco (Department: 1651)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Bacteria or actinomycetales
C514S052000
Reexamination Certificate
active
06368590
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
The present invention relates to use of a staphylococcus vaccine for the manufacture of a pharmaceutical preparation. It also related to methods for treatment and/or prevention of fibromyalgia.
BACKGROUND OF THE INVENTION
Fibromyalgia and chronic fatigue are relatively new entities in the nosology of medical disorders. They encompass conditions with symptoms such as pain, fatigue and a wide range of other symptoms which seem to have many clinical and demographic characteristics (see e.g. Buchwald D., et al., Comparison of patients with chronic fatigue syndrome, fibromyalgia and multiple chemical sensitivities, Arch. Intern. Med. 154:2049-2053, 1994). Both diseases are diagnosed on the basis of clinical criteria.
Fibromyalgia
The term fibromyalgia was first delineated in 1981 by Yunus M. B., et al., in Primary fibromyalgia (fibrositis): A clinical study of 50 patients with matched normal controls, Semin. Arthritis Rheum., 11:151-171, 1981. However, the condition has been described in the literature of medicine since the middle of the 19th century (see e.g. Simons D. G., Muscle pain syndromes—part 1, Am. J. Phys. Med., 54:289-311, 1975). Fibromyalgia is often considered as a form of non articular rheumatism, which may be connected with the formulation in the classification set forth by the American College of Rheumatology (ACR 90) (see Wolfe F., et al., The American College of Rheumatology 1990 criteria for the classification of fibromyalgia; report of the multicentre criteria committee, Arthritis Rheum., 33:160-172, 1993). The most important criteria according to The American College of Rheumatology are widespread pain and the presence of at least 11 of 18 possible tender points, so called trigger points. In the consensus report from the 2nd World Congress of Myofascial Pain and Fibromyalgia in Copenhagen, Denmark, in 1992 the disease is described as follows: a painful, nonarticular condition predominantly involving muscles—the most usual cause for widespread musculoskeletal pain. The condition normally leads to persistent fatigue, non-refreshing sleep, as well as stiffness in the whole body. Fibromyalgia is a syndrome which encompasses headaches, irritable bowels, irritable bladder, dysmenorrhoea, cold sensitivity, Raynaud's phenomenon, restless legs, atypical patterns of numbness and tingling, intolerance to physical exertion, complaints of weakness etc. A varying percentage (20-25%) of patients suffering from fibromyalgia experience significant depression or anxiety.
It is common that the symptoms vary during the day and the year. The prevalence is high. Fibromyalgia is estimated to affect 2-6% of the population (see Wolfe F., et al. The prevalence and characteristics of fibromyalgia in the general population, Arthritis Rheum., 36((9S):57, 1993, and Buskila, D., et al., Assessment of nonarticular tenderness and prevalence of fibromyalgia in children, J. Rheumatol. 20:368-370, 1993). Fibromyalgia is more common in women than in men—less than 10% of the patients with fibromyalgia are men.
The aetiology of fibromyalgia is not known, but many factors are considered to have pathological importance. Though the pain is primarily located to the muscles, research findings do not support any explanation of the syndrome that is based on only peripheral changes. The type of pain—persistent pain even when the patient is resting—and the widely spread pain and soreness points at disorders in the central nociceptive system. The idea that there may be a central sensibilisation has been put forward by Bengtsson, A, et al., in Primary fibromyalgia. A clinical and laboratory study of 55 patients, Scand. J. Rheumatol. 15:340-347, 1986. Neuroendocrinological findings, such as disturbances in the metabolism of serotonine and insufficient release of growth hormone have been discussed as possible cause of some of the manifestations of fibromyalgia (see e.g. Bennett, R. M., et al., Low levels of somatomedin C in patients with fibromyalgia syndrome, Arthritis Rheum., 32:454-460, 1992, and Russel, I. J., Biochemical abnormalities in fibromyalgia syndrome, J. Musculoskeletal Fain, 2:101-115, 1994). Immunological factors have also been suggested as possible cause (see Klein, R., et al., Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome, Psychoneuroendocrinology, 17:593:598, l992).
No curative therapy for fibromyalgia is clinically available at present; only symptomatic treatment are offered to the fibromyalgic patients. Anaigetics, i.e. anti-inflammatory drugs and paracetamol, do not seem to redice the symptoms (see Lorenzen, I., Fibromyalgia—which is the best treatment? A personalized comprehensive, ambulatory, patient-involved management programme, Balliere's Clin. Rheum., 4:333-370, 1994). Treatment with antidepressant drugs has some effects (see Jacobsen, S., Chronic widespread muscoskeletal pain—the fibromyalgia syndrome, doctoral thesis, Copenhagen: Laegeforeningens forlag, 1994). Fibromyalgic patients can often improve their physical condition by physical training.
Chronic Fatigue Syndrome
This concept was introduced in 1988 by Centers for Disease Control (see Holmes G. P., et al., Chronic fatigue syndrome: a working case definition, Ann. Intern. Med., 108:387-389, 1988>. The syndrome was thoroughly defined and the diagnostic criteria was formulated. The obligate symptom was a fatigue of an incapacitating and chronic nature that should have lasted for at least six months. Eleven minor criteria were also defined and included: mild fever or chills, sore throat, painful lymph nodes, unexplained general muscle weakness, myalgia, prolonged general fatigue after exercise, headaches, migratory arthraigia, neurophysiologic complaints and sleep disturbances. There may also be physiological signs, such low fever, non-exudative pharyngitis, and palpable or tender cervical or axillary lymph nodes. In order to diagnose a patient with chronic fatigue syndrome, the patient must fulfill eight of the eleven criteria besides the chronic fatigue, or six of the eleven criteria and two of the physiological signs.
Many physicians were critical against these criteria an variations was used both in Australia and England. This led to a new definition, which was published in December 1994, (see Fukuda, K., et al., The chronic fatigue syndrome: a comprehensive approach to its definition and study, Ann. Intern. Med., 121:953-959, 1994). The new criteria are as follows: 1a) a clinical assessed, unexplained persistent chronic fatigue, that i) the patient has not experienced earlier, ii) is not the result of ongoing exercise, iii) does not improve with rest, iv) considerably reduces the potential for the patient to carry out previous activities at work or during leisure time; 1b) the patient should also have at least four of the following six symptoms, and they should have been manifested for at least six consecutive months, but not before the onset of the fatigue, i) a self-reported impairment of the short-term memory and the concentration ability, ii) a sore throat, iii) tender cervical or axillary lymph nodes, iv) muscular aches, v) headaches of a new type and severity, vi) fatigue upon awakening, vii) a feeling of being “ill” for more than 24 hours after physical exertions
A possible connection between fatigue and infectious diseases, in particular viral diseases, has been proposed. Chronic fatigue syndrome is often considered to be the result of an acute infectious disease. Some infectious diseases that have been suggested as being of importance for chronic fatigue syndrome are infections caused by Epstein-Barr virus (EBV), human herpes virus type 6 (HBV-6), enterovirus and retrovirus, but no signs of a higher frequency of such diseases have been reported for patients suffering from chronic fatigue syndrome. There are reports on immunologic abnormalities, such as a decrease of subgroups of IgG, an increase of circulating antigen-antibody complexes, a lower activity of natural killer cells, a decrease of sub
Gottfries Carl-Gerhard
Regland Björn
Coe Susan D.
Orum & Roth
Prats Francisco
LandOfFree
Pharmaceutical preparation and method for treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical preparation and method for treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical preparation and method for treatment and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2840335